Chemotherapy Induced Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chemotherapy induced neutropenia pipeline market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.
Key Targets in the Chemotherapy Induced Neutropenia Pipeline Market
The key targets in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5. Granulocyte Colony Stimulating Factor Receptor has the highest number of pipeline products.
Chemotherapy Induced Neutropenia Pipeline Market, by Target
For more target insights, download a free report sample
Key MoA in the Chemotherapy Induced Neutropenia Pipeline Market
The key MoA in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator. Granulocyte Colony Stimulating Factor Receptor Agonist have the highest number of pipeline products.
Chemotherapy Induced Neutropenia Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Chemotherapy Induced Neutropenia Pipeline Market
The key RoA in the chemotherapy induced neutropenia pipeline market are subcutaneous, intravenous, oral, and intramuscular. Subcutaneous has the highest number of pipeline products.
Chemotherapy Induced Neutropenia Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Chemotherapy Induced Neutropenia Pipeline Market
The key molecule type in the chemotherapy induced neutropenia pipeline market are recombinant protein, fusion protein, small molecule, and cell therapy. Recombinant protein has the highest number of pipeline products.
Chemotherapy Induced Neutropenia Pipeline Market, by Molecule Type
For more insights, download a free report sample
Key Companies in the Chemotherapy Induced Neutropenia Pipeline Market
The key companies in the chemotherapy induced neutropenia pipeline market are Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd. Curateq Biologics Pvt Ltd has the highest number of pipeline products.
Chemotherapy Induced Neutropenia Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
Key targets | Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5 |
Key MoA | Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator |
Key RoA | Subcutaneous, Intravenous, Oral, and Intramuscular |
Key molecule types | Recombinant Protein, Fusion Protein, Small Molecule, and Cell Therapy |
Key companies | Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
BeyondSpring Inc
Biocon Ltd
Biosimilar Solutions LLC
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
CSPC Pharmaceutical Group Ltd
Curateq Biologics Pvt Ltd
Dr. Reddy's Laboratories Ltd
Enzychem Lifesciences Corp
Evive Biotech
FortuneRock (China) Ltd
General Regeneratives Shanghai Ltd
GlycoMimetics Inc
Hangzhou Jiuyuan Gene Engineering Co Ltd
Hanmi Pharmaceuticals Co Ltd
Ilkogen Ilac San Ve Tic AS
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Karyo Biologics LLC
Kidswell Bio Corp
Ligand Pharmaceuticals Inc
Lupin Ltd
Mabwell Shanghai Bioscience Co Ltd
Mycenax Biotech Inc
Pangen Biotech Inc
Profarma
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Siam Bioscience Co Ltd
Tanvex BioPharma Inc
UBI Pharma Inc
USV Pvt Ltd
Valenta Pharm
Xiamen Amoytop Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the chemotherapy induced neutropenia pipeline market?
The key targets in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor, Caspase 3, Caspase 8, Caspase 9, Rho Guanine Nucleotide Exchange Factor 2, E Selectin, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha, Interleukin 1 Receptor, Signal Transducer And Activator Of Transcription, Signal Transducer and Activator Of Transcription 5.
-
What are the key MoA in the chemotherapy induced neutropenia pipeline market?
The key MoA in the chemotherapy induced neutropenia pipeline market are Granulocyte Colony Stimulating Factor Receptor Agonist, Caspase 3 Activator, Caspase 8 Activator, Caspase 9 Activator, Granulocyte Macrophage Colony Stimulating Factor, Receptor Subunit Alpha Agonist, and Rho Guanine Nucleotide Exchange Factor 2 Activator.
-
What are the key RoA in the chemotherapy induced neutropenia pipeline market?
The key RoA in the chemotherapy induced neutropenia pipeline market are subcutaneous, intravenous, oral, and intramuscular.
-
What are the Key molecule type in the chemotherapy induced neutropenia pipeline market?
The key molecule type in the chemotherapy induced neutropenia pipeline market are recombinant protein, fusion protein, small molecule, and cell therapy.
-
What are the key companies in the chemotherapy induced neutropenia pipeline market?
The key companies in the chemotherapy induced neutropenia pipeline market are Curateq Biologics Pvt Ltd, Hanmi Pharmaceuticals Co Ltd, USV Pvt Ltd, BeyondSpring Inc, Biocon Ltd 1, Bolder Biotechnology Inc, Evive Biotech, and Lupin Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.